Status: Recruiting
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), that is incurable or not resectable with curative intent.
Participants needed: 148
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: St. Olavs HospitalUpdated: May 25, 2025Locations: 1
Eligibility criteria
Age 18 or older [+11]
Patient has metastatic MMR deficient/MSI adenocarcinoma [+20]